382 related articles for article (PubMed ID: 35316503)
1. Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
Kuwana M; Saito A; Sakamoto W; Raabe C; Saito K
Adv Ther; 2022 May; 39(5):2222-2235. PubMed ID: 35316503
[TBL] [Abstract][Full Text] [Related]
2. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
[TBL] [Abstract][Full Text] [Related]
3. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States.
Fan Y; Bender S; Shi W; Zoz D
J Manag Care Spec Pharm; 2020 Dec; 26(12):1539-1547. PubMed ID: 32996805
[TBL] [Abstract][Full Text] [Related]
4. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
[TBL] [Abstract][Full Text] [Related]
5. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis.
Tomiyama F; Watanabe R; Ishii T; Kamogawa Y; Fujita Y; Shirota Y; Sugimura K; Fujii H; Harigae H
Tohoku J Exp Med; 2016 Aug; 239(4):297-305. PubMed ID: 27487743
[TBL] [Abstract][Full Text] [Related]
6. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Narita Y; Funatogawa T; Mii K; Adachi H; Tamura A; Yamakido S
Mod Rheumatol; 2023 Apr; 33(3):525-532. PubMed ID: 35652700
[TBL] [Abstract][Full Text] [Related]
7. Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years.
Pope JE; Quansah K; Hassan S; Seung SJ; Flavin J; Kolb M
J Rheumatol; 2021 Sep; 48(9):1427-1434. PubMed ID: 33795325
[TBL] [Abstract][Full Text] [Related]
8. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.
Zhou Z; Fan Y; Thomason D; Tang W; Liu X; Zhou ZY; Macaulay D; Fischer A
Adv Ther; 2019 May; 36(5):1100-1113. PubMed ID: 30929184
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis.
Qiu M; Nian X; Pang L; Yu P; Zou S
Int J Rheum Dis; 2021 Dec; 24(12):1449-1459. PubMed ID: 34418313
[TBL] [Abstract][Full Text] [Related]
11. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
12. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
[TBL] [Abstract][Full Text] [Related]
13. Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study.
Knarborg M; Hyldgaard C; Bendstrup E; Davidsen JR; Løkke A; Shaker SB; Hilberg O
Chron Respir Dis; 2022; 19():14799731221125559. PubMed ID: 36123773
[TBL] [Abstract][Full Text] [Related]
14. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
[TBL] [Abstract][Full Text] [Related]
15. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
[TBL] [Abstract][Full Text] [Related]
16. Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data.
Knarborg M; Hyldgaard C; Bendstrup E; Davidsen JR; Løkke A; Shaker SB; Hilberg O
Chron Respir Dis; 2023; 20():14799731231195041. PubMed ID: 37596992
[TBL] [Abstract][Full Text] [Related]
17. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region.
Lescoat A; Huscher D; Schoof N; Airò P; de Vries-Bouwstra J; Riemekasten G; Hachulla E; Doria A; Rosato E; Hunzelmann N; Montecucco C; Gabrielli A; Hoffmann-Vold AM; Distler O; Ben Shimol J; Cutolo M; Allanore Y;
Rheumatology (Oxford); 2023 Jun; 62(6):2178-2188. PubMed ID: 36222557
[TBL] [Abstract][Full Text] [Related]
18. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
20. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
